No Data
JMP Securities Maintains Cue Biopharma(CUE.US) With Buy Rating, Maintains Target Price $15
JMP Securities analyst Reni Benjamin maintains $Cue Biopharma(CUE.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 33.1% and
Express News | Cue Biopharma Presents Updated Data From Phase 1 Trial of Cue-101 in Recurrent/Metastatic Hpv+ Head and Neck Cancer at the 2024 Asco Annual Meeting
Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Express News | Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results